Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues

The anti-fibrotic drug pirfenidone (PFD) is currently in clinical testing for the treatment of heart failure with preserved ejection fraction; however, its effects on human cardiac cells have not been fully investigated. Therefore, we aimed to characterize the impact of PFD on human cardiac fibrobla...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Friederike Elisabeth Ugi, Santos, Gabriela Leao, Doan, Thao Phuong, DeGrave, Alisa Nicole, Bues, Bastian, Lutz, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338590/
https://www.ncbi.nlm.nih.gov/pubmed/36800014
http://dx.doi.org/10.1007/s00210-023-02421-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338590/
https://www.ncbi.nlm.nih.gov/pubmed/36800014
http://dx.doi.org/10.1007/s00210-023-02421-9

Ejemplares similares